| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ca886b4e503610ba43da2c3550a5cf2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23G3-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23G3-364
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23G3-0053 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23G3-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23G3-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate |
2017-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d38ddebc01b417142f91b56fb48c4d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc31a3644cbca2fed0ab2cf4c00b4339
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7dc19fb24cc7f6759a526364d511f5b3 |
| publicationDate |
2018-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10034832-B2 |
| titleOfInvention |
Sublingual antidepressant lozenge |
| abstract |
Technologies are described for formulations and methods to produce sublingual antidepressant lozenges. The lozenges may comprise troche base and ketamine. The lozenges may comprise 0.35 weight percent to 0.65 weight percent ketamine. The methods may comprise placing troche base into a chamber. The methods may comprise applying heat to the chamber. The heat may be sufficient to melt the troche base in the chamber. The methods may comprise adding a first ingredient into the chamber. The first ingredient may include ketamine. The methods may comprise mixing the first ingredient into the melted troche base in the chamber to form a melted mixture. The methods may comprise pouring the melted mixture into a mold. The methods may comprise cooling the melted mixture in the mold to form the lozenge. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11324707-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022238507-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022248621-A1 |
| priorityDate |
2016-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |